Búsqueda Imágenes Maps Play YouTube Noticias Gmail Drive Más »
Iniciar sesión
Usuarios de lectores de pantalla: deben hacer clic en este enlace para utilizar el modo de accesibilidad. Este modo tiene las mismas funciones esenciales pero funciona mejor con el lector.

Patentes

  1. Búsqueda avanzada de patentes
Número de publicaciónWO1999055715 A2
Tipo de publicaciónSolicitud
Número de solicitudPCT/US1999/009164
Fecha de publicación4 Nov 1999
Fecha de presentación28 Abr 1999
Fecha de prioridad28 Abr 1998
También publicado comoCA2329897A1, EP1073667A2, US6573245, WO1999055715A3
Número de publicaciónPCT/1999/9164, PCT/US/1999/009164, PCT/US/1999/09164, PCT/US/99/009164, PCT/US/99/09164, PCT/US1999/009164, PCT/US1999/09164, PCT/US1999009164, PCT/US199909164, PCT/US99/009164, PCT/US99/09164, PCT/US99009164, PCT/US9909164, WO 1999/055715 A2, WO 1999055715 A2, WO 1999055715A2, WO 9955715 A2, WO 9955715A2, WO-A2-1999055715, WO-A2-9955715, WO1999/055715A2, WO1999055715 A2, WO1999055715A2, WO9955715 A2, WO9955715A2
InventoresDante J. Marciani
SolicitanteGalenica Pharmaceuticals, Inc.
Exportar citaBiBTeX, EndNote, RefMan
Enlaces externos:  Patentscope, Espacenet
Polysaccharide-antigen conjugates
WO 1999055715 A2
Descripción  disponible en inglés
Reclamaciones  disponible en inglés
Citas de patentes
Patente citada Fecha de presentación Fecha de publicación Solicitante Título
WO1996040225A1 *6 Jun 199619 Dic 1996Alberta Research CouncilImmunogenic and immunostimulatory oligosaccharide compositions and methods of making and using them
WO1997033612A1 *13 Mar 199718 Sep 1997Immunotherapy, Inc.Dialdehydes as immunostimulatory adjuvants and cross-linkers for producing immunogenic preparations and generating pressure and cross-link treated cells for enhancing and augmenting the immune response against cancers, tumors and pathogenic diseases
WO1999017783A1 *2 Oct 199815 Abr 1999Galenica Pharmaceuticals, Inc.Imine-forming polysaccharides, preparation thereof and the use thereof as adjuvants and immunostimulants
US4356170 *27 May 198126 Oct 1982Canadian Patents & Development Ltd.Immunogenic polysaccharide-protein conjugates
Otras citas
Referencia
1 *GOOD A H ET AL: "IDENTIFICATION OF CARBOHYDRATE STRUCTURES THAT BIND HUMAN ANTIPORCINE ANTIBODIES: IMPLICATIONS FOR DISCORDANT XENOGRAFTING INHUMANS" TRANSPLANTATION PROCEEDINGS, vol. 24, no. 2, April 1992 (1992-04), pages 559-562, XP002916011 ISSN: 0041-1345
2 *KOLAR C ET AL: "PREPARATION AND USE OF SYNTHETIC BLOOD GROUP SPECIFIC IMMUNOADSORBENTS" BEHRING INSTITUTE: MITTEILUNGEN, vol. 82, 1988, pages 94-103, XP002916010
3 *STAHL P D: "THE MANNOSE RECEPTOR AND OTHER MACROPHAGE LECTINS" CURRENT OPINION IN IMMUNOLOGY, vol. 4, no. 1, 1 February 1992 (1992-02-01), pages 49-52, XP000647872 ISSN: 0952-7915 cited in the application
Citada por
Patente citante Fecha de presentación Fecha de publicación Solicitante Título
WO2001012218A1 *10 Mar 200022 Feb 2001Zonagen, Inc.Methods and materials for the treatment of prostatic carcinoma
WO2001093912A1 *6 Jun 200113 Dic 2001The Austin Research InstituteVaccine
WO2003097091A2 *15 May 200327 Nov 2003Luciano PolonelliGlucan-based vaccines
WO2003097091A3 *15 May 20034 Mar 2004Luciano PolonelliGlucan-based vaccines
WO2007000343A3 *23 Jun 200631 May 2007Glaxosmithkline Biolog SaProcess for manufacturing vaccines
WO2007049269A1 *21 Jun 20063 May 2007Bio-Rad Haifa Ltd.Binding layer and method for its preparation and uses thereof
WO2008081014A2 *2 Ene 200810 Jul 2008Glaxosmithkline Biologicals S.A.Process for manufacturing vaccines
WO2008081014A3 *2 Ene 200821 Ago 2008Glaxosmithkline Biolog SaProcess for manufacturing vaccines
WO2008081022A1 *2 Ene 200810 Jul 2008Glaxosmithkline Biologicals S.A.Vaccine
EP1891970A1 *15 May 200327 Feb 2008Luciano PolonelliBeta glucan-based vaccines free of mannoprotein
EP2351578A1 *23 Jun 20063 Ago 2011GlaxoSmithKline Biologicals S.A.Process for manufacturing vaccines
US695611921 Mar 200118 Oct 2005Hans LoibnerPolysaccharide-polypeptide conjugate
US78246881 Feb 20072 Nov 2010Antonio CassoneGlucan-based vaccines
US789321914 Sep 200522 Feb 2011Novartis Vaccines & Diagnostics, Inc.Protective anti-glucan antibodies with preference for β-1,3- glucans
US81014066 Ago 201024 Ene 2012Novartis Vaccines And Diagnostics, Inc.Protective anti-glucan antibodies with preference for β-1,3-glucans
US815313513 Sep 200510 Abr 2012Hans LoibnerPolysaccharide-polypeptide conjugate
US81828212 Oct 200722 May 2012The Macfarlane Burnet Institute For Medical Research And Public Health Ltd.Flu vaccine admixture of mannan and flu antigen
US832918423 Jun 200611 Dic 2012Glaxosmithkline Biologicals S.A.Process for manufacturing vaccines
US839899011 Ago 201019 Mar 2013Antonio CassoneGlucan-based vaccines
US841488920 Dic 20119 Abr 2013Antonio CassoneProtective anti-glucan antibodies with preference for β-1,3-glucans
US867950626 Feb 201325 Mar 2014Antonio CassoneGlucan-based vaccines
US884604927 Abr 201230 Sep 2014Glaxosmithkline Biologicals S.A.Process for manufacturing vaccines
US904030921 Jun 200626 May 2015Bio-Rad Haifa Ltd.Binding layer and method for its preparation and uses thereof
US953921015 Mar 201310 Ene 2017Massachusetts Institute Of TechnologyVaccine nanotechnology
Eventos legales
FechaCódigoEventoDescripción
4 Nov 1999AKDesignated states
Kind code of ref document: A2
Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW
4 Nov 1999ALDesignated countries for regional patents
Kind code of ref document: A2
Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
29 Dic 1999AKDesignated states
Kind code of ref document: A3
Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW
29 Dic 1999121Ep: the epo has been informed by wipo that ep was designated in this application
29 Dic 1999ALDesignated countries for regional patents
Kind code of ref document: A3
Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG
20 Ene 2000DFPERequest for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
25 Oct 2000ENPEntry into the national phase in:
Ref document number: 2329897
Country of ref document: CA
26 Oct 2000ENPEntry into the national phase in:
Ref country code: JP
Ref document number: 2000 545873
Kind code of ref document: A
Format of ref document f/p: F
28 Oct 2000NENPNon-entry into the national phase in:
Ref country code: KR
21 Nov 2000WWEWipo information: entry into national phase
Ref document number: 37676/99
Country of ref document: AU
27 Nov 2000WWEWipo information: entry into national phase
Ref document number: 1999920096
Country of ref document: EP
7 Feb 2001WWPWipo information: published in national office
Ref document number: 1999920096
Country of ref document: EP
1 Mar 2001REGReference to national code
Ref country code: DE
Ref legal event code: 8642
4 Sep 2003WWGWipo information: grant in national office
Ref document number: 37676/99
Country of ref document: AU
15 Ago 2006WWWWipo information: withdrawn in national office
Ref document number: 1999920096
Country of ref document: EP